nodes	percent_of_prediction	percent_of_DWPC	metapath
Nabumetone—PTGS1—kidney cancer	0.431	0.636	CbGaD
Nabumetone—PTGS2—kidney cancer	0.247	0.364	CbGaD
Nabumetone—CYP1A2—Pazopanib—kidney cancer	0.0138	0.436	CbGbCtD
Nabumetone—CYP1A2—Erlotinib—kidney cancer	0.00983	0.311	CbGbCtD
Nabumetone—CYP1A2—Sorafenib—kidney cancer	0.00799	0.253	CbGbCtD
Nabumetone—Naproxen—PTGS1—kidney cancer	0.000659	0.424	CrCbGaD
Nabumetone—Melatonin—CYP1A1—kidney cancer	0.000519	0.334	CrCbGaD
Nabumetone—Naproxen—PTGS2—kidney cancer	0.000377	0.242	CrCbGaD
Nabumetone—Increased appetite—Doxorubicin—kidney cancer	0.000171	0.000717	CcSEcCtD
Nabumetone—Hypersensitivity—Sorafenib—kidney cancer	0.00017	0.000713	CcSEcCtD
Nabumetone—Insomnia—Vincristine—kidney cancer	0.00017	0.000713	CcSEcCtD
Nabumetone—Anorexia—Gemcitabine—kidney cancer	0.00017	0.000713	CcSEcCtD
Nabumetone—Vomiting—Vinblastine—kidney cancer	0.000169	0.000712	CcSEcCtD
Nabumetone—Dizziness—Erlotinib—kidney cancer	0.000169	0.000712	CcSEcCtD
Nabumetone—Ill-defined disorder—Paclitaxel—kidney cancer	0.000169	0.000712	CcSEcCtD
Nabumetone—Vomiting—Everolimus—kidney cancer	0.000169	0.000709	CcSEcCtD
Nabumetone—Anaemia—Paclitaxel—kidney cancer	0.000169	0.000709	CcSEcCtD
Nabumetone—Paraesthesia—Vincristine—kidney cancer	0.000168	0.000708	CcSEcCtD
Nabumetone—Dermatitis bullous—Doxorubicin—kidney cancer	0.000168	0.000705	CcSEcCtD
Nabumetone—Agitation—Paclitaxel—kidney cancer	0.000168	0.000705	CcSEcCtD
Nabumetone—Rash—Everolimus—kidney cancer	0.000167	0.000703	CcSEcCtD
Nabumetone—Dermatitis—Everolimus—kidney cancer	0.000167	0.000703	CcSEcCtD
Nabumetone—Headache—Vinblastine—kidney cancer	0.000167	0.000702	CcSEcCtD
Nabumetone—Angioedema—Paclitaxel—kidney cancer	0.000167	0.000701	CcSEcCtD
Nabumetone—Headache—Everolimus—kidney cancer	0.000166	0.000699	CcSEcCtD
Nabumetone—Abdominal pain—Dactinomycin—kidney cancer	0.000166	0.000697	CcSEcCtD
Nabumetone—Body temperature increased—Dactinomycin—kidney cancer	0.000166	0.000697	CcSEcCtD
Nabumetone—Visual impairment—Capecitabine—kidney cancer	0.000166	0.000697	CcSEcCtD
Nabumetone—Anaphylactoid reaction—Doxorubicin—kidney cancer	0.000166	0.000696	CcSEcCtD
Nabumetone—Asthenia—Sorafenib—kidney cancer	0.000165	0.000695	CcSEcCtD
Nabumetone—Malaise—Paclitaxel—kidney cancer	0.000165	0.000692	CcSEcCtD
Nabumetone—Vertigo—Paclitaxel—kidney cancer	0.000164	0.000689	CcSEcCtD
Nabumetone—Syncope—Paclitaxel—kidney cancer	0.000164	0.000688	CcSEcCtD
Nabumetone—Leukopenia—Paclitaxel—kidney cancer	0.000163	0.000687	CcSEcCtD
Nabumetone—Hypersensitivity—Sunitinib—kidney cancer	0.000163	0.000686	CcSEcCtD
Nabumetone—Decreased appetite—Vincristine—kidney cancer	0.000163	0.000685	CcSEcCtD
Nabumetone—Pruritus—Sorafenib—kidney cancer	0.000163	0.000685	CcSEcCtD
Nabumetone—Vomiting—Erlotinib—kidney cancer	0.000163	0.000684	CcSEcCtD
Nabumetone—Erythema multiforme—Capecitabine—kidney cancer	0.000163	0.000684	CcSEcCtD
Nabumetone—Fatigue—Vincristine—kidney cancer	0.000162	0.000679	CcSEcCtD
Nabumetone—Rash—Erlotinib—kidney cancer	0.000161	0.000679	CcSEcCtD
Nabumetone—Dermatitis—Erlotinib—kidney cancer	0.000161	0.000678	CcSEcCtD
Nabumetone—Palpitations—Paclitaxel—kidney cancer	0.000161	0.000678	CcSEcCtD
Nabumetone—Insomnia—Gemcitabine—kidney cancer	0.000161	0.000676	CcSEcCtD
Nabumetone—Headache—Erlotinib—kidney cancer	0.00016	0.000674	CcSEcCtD
Nabumetone—Tinnitus—Capecitabine—kidney cancer	0.00016	0.000674	CcSEcCtD
Nabumetone—Loss of consciousness—Paclitaxel—kidney cancer	0.00016	0.000674	CcSEcCtD
Nabumetone—Constipation—Vincristine—kidney cancer	0.00016	0.000674	CcSEcCtD
Nabumetone—Gastrointestinal haemorrhage—Doxorubicin—kidney cancer	0.00016	0.000674	CcSEcCtD
Nabumetone—Paraesthesia—Gemcitabine—kidney cancer	0.00016	0.000671	CcSEcCtD
Nabumetone—Cough—Paclitaxel—kidney cancer	0.000159	0.000669	CcSEcCtD
Nabumetone—Asthenia—Sunitinib—kidney cancer	0.000159	0.000669	CcSEcCtD
Nabumetone—Dyspnoea—Gemcitabine—kidney cancer	0.000159	0.000667	CcSEcCtD
Nabumetone—Nausea—Vinblastine—kidney cancer	0.000158	0.000665	CcSEcCtD
Nabumetone—Somnolence—Gemcitabine—kidney cancer	0.000158	0.000665	CcSEcCtD
Nabumetone—Nausea—Everolimus—kidney cancer	0.000158	0.000663	CcSEcCtD
Nabumetone—Diarrhoea—Sorafenib—kidney cancer	0.000158	0.000663	CcSEcCtD
Nabumetone—Hypertension—Paclitaxel—kidney cancer	0.000158	0.000662	CcSEcCtD
Nabumetone—Pruritus—Sunitinib—kidney cancer	0.000157	0.000659	CcSEcCtD
Nabumetone—Anxiety—Paclitaxel—kidney cancer	0.000155	0.000651	CcSEcCtD
Nabumetone—Decreased appetite—Gemcitabine—kidney cancer	0.000155	0.00065	CcSEcCtD
Nabumetone—Hypersensitivity—Dactinomycin—kidney cancer	0.000155	0.00065	CcSEcCtD
Nabumetone—Chills—Capecitabine—kidney cancer	0.000154	0.000649	CcSEcCtD
Nabumetone—Arrhythmia—Capecitabine—kidney cancer	0.000154	0.000646	CcSEcCtD
Nabumetone—Discomfort—Paclitaxel—kidney cancer	0.000153	0.000645	CcSEcCtD
Nabumetone—Fatigue—Gemcitabine—kidney cancer	0.000153	0.000645	CcSEcCtD
Nabumetone—Gastrointestinal pain—Vincristine—kidney cancer	0.000153	0.000644	CcSEcCtD
Nabumetone—Dizziness—Sorafenib—kidney cancer	0.000152	0.00064	CcSEcCtD
Nabumetone—Constipation—Gemcitabine—kidney cancer	0.000152	0.000639	CcSEcCtD
Nabumetone—Nausea—Erlotinib—kidney cancer	0.000152	0.000639	CcSEcCtD
Nabumetone—Alopecia—Capecitabine—kidney cancer	0.000152	0.000639	CcSEcCtD
Nabumetone—Dry mouth—Paclitaxel—kidney cancer	0.000152	0.000639	CcSEcCtD
Nabumetone—Diarrhoea—Sunitinib—kidney cancer	0.000152	0.000638	CcSEcCtD
Nabumetone—Asthenia—Dactinomycin—kidney cancer	0.000151	0.000633	CcSEcCtD
Nabumetone—Confusional state—Paclitaxel—kidney cancer	0.00015	0.000631	CcSEcCtD
Nabumetone—Anaphylactic shock—Paclitaxel—kidney cancer	0.000149	0.000626	CcSEcCtD
Nabumetone—Oedema—Paclitaxel—kidney cancer	0.000149	0.000626	CcSEcCtD
Nabumetone—Abdominal pain—Vincristine—kidney cancer	0.000148	0.000623	CcSEcCtD
Nabumetone—Body temperature increased—Vincristine—kidney cancer	0.000148	0.000623	CcSEcCtD
Nabumetone—Liver function test abnormal—Doxorubicin—kidney cancer	0.000148	0.000622	CcSEcCtD
Nabumetone—Flatulence—Capecitabine—kidney cancer	0.000148	0.00062	CcSEcCtD
Nabumetone—Dizziness—Sunitinib—kidney cancer	0.000147	0.000616	CcSEcCtD
Nabumetone—Feeling abnormal—Gemcitabine—kidney cancer	0.000147	0.000616	CcSEcCtD
Nabumetone—Shock—Paclitaxel—kidney cancer	0.000147	0.000616	CcSEcCtD
Nabumetone—Vomiting—Sorafenib—kidney cancer	0.000146	0.000616	CcSEcCtD
Nabumetone—Hypokalaemia—Doxorubicin—kidney cancer	0.000146	0.000613	CcSEcCtD
Nabumetone—Thrombocytopenia—Paclitaxel—kidney cancer	0.000146	0.000613	CcSEcCtD
Nabumetone—Rash—Sorafenib—kidney cancer	0.000145	0.000611	CcSEcCtD
Nabumetone—Dermatitis—Sorafenib—kidney cancer	0.000145	0.00061	CcSEcCtD
Nabumetone—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	0.000144	0.000607	CcSEcCtD
Nabumetone—Headache—Sorafenib—kidney cancer	0.000144	0.000607	CcSEcCtD
Nabumetone—Hyperhidrosis—Paclitaxel—kidney cancer	0.000144	0.000605	CcSEcCtD
Nabumetone—Diarrhoea—Dactinomycin—kidney cancer	0.000144	0.000604	CcSEcCtD
Nabumetone—Anorexia—Paclitaxel—kidney cancer	0.000142	0.000597	CcSEcCtD
Nabumetone—Gastritis—Doxorubicin—kidney cancer	0.000142	0.000596	CcSEcCtD
Nabumetone—Vomiting—Sunitinib—kidney cancer	0.000141	0.000592	CcSEcCtD
Nabumetone—Body temperature increased—Gemcitabine—kidney cancer	0.000141	0.000591	CcSEcCtD
Nabumetone—Tremor—Capecitabine—kidney cancer	0.00014	0.00059	CcSEcCtD
Nabumetone—Rash—Sunitinib—kidney cancer	0.00014	0.000587	CcSEcCtD
Nabumetone—Dermatitis—Sunitinib—kidney cancer	0.00014	0.000587	CcSEcCtD
Nabumetone—Ill-defined disorder—Capecitabine—kidney cancer	0.000139	0.000584	CcSEcCtD
Nabumetone—Headache—Sunitinib—kidney cancer	0.000139	0.000584	CcSEcCtD
Nabumetone—Dysphagia—Doxorubicin—kidney cancer	0.000139	0.000582	CcSEcCtD
Nabumetone—Asthma—Doxorubicin—kidney cancer	0.000139	0.000582	CcSEcCtD
Nabumetone—Anaemia—Capecitabine—kidney cancer	0.000138	0.000582	CcSEcCtD
Nabumetone—Hypersensitivity—Vincristine—kidney cancer	0.000138	0.000581	CcSEcCtD
Nabumetone—Nausea—Sorafenib—kidney cancer	0.000137	0.000575	CcSEcCtD
Nabumetone—Pancreatitis—Doxorubicin—kidney cancer	0.000136	0.000571	CcSEcCtD
Nabumetone—Malaise—Capecitabine—kidney cancer	0.000135	0.000568	CcSEcCtD
Nabumetone—Angina pectoris—Doxorubicin—kidney cancer	0.000135	0.000567	CcSEcCtD
Nabumetone—Insomnia—Paclitaxel—kidney cancer	0.000135	0.000566	CcSEcCtD
Nabumetone—Vertigo—Capecitabine—kidney cancer	0.000135	0.000565	CcSEcCtD
Nabumetone—Asthenia—Vincristine—kidney cancer	0.000135	0.000565	CcSEcCtD
Nabumetone—Syncope—Capecitabine—kidney cancer	0.000134	0.000564	CcSEcCtD
Nabumetone—Leukopenia—Capecitabine—kidney cancer	0.000134	0.000563	CcSEcCtD
Nabumetone—Paraesthesia—Paclitaxel—kidney cancer	0.000134	0.000562	CcSEcCtD
Nabumetone—Vomiting—Dactinomycin—kidney cancer	0.000133	0.000561	CcSEcCtD
Nabumetone—Dyspnoea—Paclitaxel—kidney cancer	0.000133	0.000558	CcSEcCtD
Nabumetone—Somnolence—Paclitaxel—kidney cancer	0.000132	0.000556	CcSEcCtD
Nabumetone—Palpitations—Capecitabine—kidney cancer	0.000132	0.000556	CcSEcCtD
Nabumetone—Rash—Dactinomycin—kidney cancer	0.000132	0.000556	CcSEcCtD
Nabumetone—Nausea—Sunitinib—kidney cancer	0.000132	0.000553	CcSEcCtD
Nabumetone—Loss of consciousness—Capecitabine—kidney cancer	0.000132	0.000553	CcSEcCtD
Nabumetone—Dyspepsia—Paclitaxel—kidney cancer	0.000131	0.000551	CcSEcCtD
Nabumetone—Cough—Capecitabine—kidney cancer	0.000131	0.000549	CcSEcCtD
Nabumetone—Dysuria—Doxorubicin—kidney cancer	0.00013	0.000544	CcSEcCtD
Nabumetone—Decreased appetite—Paclitaxel—kidney cancer	0.000129	0.000544	CcSEcCtD
Nabumetone—Hypertension—Capecitabine—kidney cancer	0.000129	0.000543	CcSEcCtD
Nabumetone—Fatigue—Paclitaxel—kidney cancer	0.000128	0.00054	CcSEcCtD
Nabumetone—Diarrhoea—Vincristine—kidney cancer	0.000128	0.000539	CcSEcCtD
Nabumetone—Asthenia—Gemcitabine—kidney cancer	0.000128	0.000536	CcSEcCtD
Nabumetone—Constipation—Paclitaxel—kidney cancer	0.000127	0.000535	CcSEcCtD
Nabumetone—Anxiety—Capecitabine—kidney cancer	0.000127	0.000534	CcSEcCtD
Nabumetone—Photosensitivity reaction—Doxorubicin—kidney cancer	0.000126	0.000531	CcSEcCtD
Nabumetone—Weight increased—Doxorubicin—kidney cancer	0.000126	0.00053	CcSEcCtD
Nabumetone—Discomfort—Capecitabine—kidney cancer	0.000126	0.000529	CcSEcCtD
Nabumetone—Pruritus—Gemcitabine—kidney cancer	0.000126	0.000529	CcSEcCtD
Nabumetone—Weight decreased—Doxorubicin—kidney cancer	0.000125	0.000527	CcSEcCtD
Nabumetone—Hyperglycaemia—Doxorubicin—kidney cancer	0.000125	0.000525	CcSEcCtD
Nabumetone—Dry mouth—Capecitabine—kidney cancer	0.000125	0.000524	CcSEcCtD
Nabumetone—Nausea—Dactinomycin—kidney cancer	0.000125	0.000524	CcSEcCtD
Nabumetone—Pneumonia—Doxorubicin—kidney cancer	0.000124	0.000522	CcSEcCtD
Nabumetone—Dizziness—Vincristine—kidney cancer	0.000124	0.000521	CcSEcCtD
Nabumetone—Confusional state—Capecitabine—kidney cancer	0.000123	0.000518	CcSEcCtD
Nabumetone—Feeling abnormal—Paclitaxel—kidney cancer	0.000123	0.000516	CcSEcCtD
Nabumetone—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	0.000122	0.000515	CcSEcCtD
Nabumetone—Oedema—Capecitabine—kidney cancer	0.000122	0.000514	CcSEcCtD
Nabumetone—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000122	0.000512	CcSEcCtD
Nabumetone—Diarrhoea—Gemcitabine—kidney cancer	0.000122	0.000512	CcSEcCtD
Nabumetone—Renal failure—Doxorubicin—kidney cancer	0.000121	0.00051	CcSEcCtD
Nabumetone—Jaundice—Doxorubicin—kidney cancer	0.00012	0.000506	CcSEcCtD
Nabumetone—Stomatitis—Doxorubicin—kidney cancer	0.00012	0.000506	CcSEcCtD
Nabumetone—Shock—Capecitabine—kidney cancer	0.00012	0.000505	CcSEcCtD
Nabumetone—Thrombocytopenia—Capecitabine—kidney cancer	0.00012	0.000503	CcSEcCtD
Nabumetone—Vomiting—Vincristine—kidney cancer	0.000119	0.000501	CcSEcCtD
Nabumetone—Urticaria—Paclitaxel—kidney cancer	0.000118	0.000497	CcSEcCtD
Nabumetone—CYP1A2—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	0.000118	0.00233	CbGpPWpGaD
Nabumetone—Rash—Vincristine—kidney cancer	0.000118	0.000497	CcSEcCtD
Nabumetone—Hyperhidrosis—Capecitabine—kidney cancer	0.000118	0.000497	CcSEcCtD
Nabumetone—Dermatitis—Vincristine—kidney cancer	0.000118	0.000496	CcSEcCtD
Nabumetone—Haematuria—Doxorubicin—kidney cancer	0.000118	0.000495	CcSEcCtD
Nabumetone—Abdominal pain—Paclitaxel—kidney cancer	0.000118	0.000495	CcSEcCtD
Nabumetone—Body temperature increased—Paclitaxel—kidney cancer	0.000118	0.000495	CcSEcCtD
Nabumetone—Headache—Vincristine—kidney cancer	0.000117	0.000494	CcSEcCtD
Nabumetone—Anorexia—Capecitabine—kidney cancer	0.000116	0.00049	CcSEcCtD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—CYP1A1—kidney cancer	0.000116	0.0023	CbGpPWpGaD
Nabumetone—CYP1A2—Tryptophan metabolism—CYP1A1—kidney cancer	0.000116	0.0023	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1A1—kidney cancer	0.000116	0.0023	CbGpPWpGaD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—CDKN1B—kidney cancer	0.000116	0.00228	CbGpPWpGaD
Nabumetone—Agranulocytosis—Doxorubicin—kidney cancer	0.000115	0.000485	CcSEcCtD
Nabumetone—CYP1A2—Phase II conjugation—GSTT1—kidney cancer	0.000115	0.00226	CbGpPWpGaD
Nabumetone—CYP1A2—Biological oxidations—ALDH1A1—kidney cancer	0.000114	0.00225	CbGpPWpGaD
Nabumetone—Vomiting—Gemcitabine—kidney cancer	0.000113	0.000475	CcSEcCtD
Nabumetone—Rash—Gemcitabine—kidney cancer	0.000112	0.000471	CcSEcCtD
Nabumetone—Dermatitis—Gemcitabine—kidney cancer	0.000112	0.000471	CcSEcCtD
Nabumetone—Haemoglobin—Doxorubicin—kidney cancer	0.000111	0.000468	CcSEcCtD
Nabumetone—Headache—Gemcitabine—kidney cancer	0.000111	0.000468	CcSEcCtD
Nabumetone—Nausea—Vincristine—kidney cancer	0.000111	0.000468	CcSEcCtD
Nabumetone—Haemorrhage—Doxorubicin—kidney cancer	0.000111	0.000466	CcSEcCtD
Nabumetone—Insomnia—Capecitabine—kidney cancer	0.000111	0.000465	CcSEcCtD
Nabumetone—Paraesthesia—Capecitabine—kidney cancer	0.00011	0.000461	CcSEcCtD
Nabumetone—Hypersensitivity—Paclitaxel—kidney cancer	0.00011	0.000461	CcSEcCtD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—ACHE—kidney cancer	0.000109	0.00215	CbGpPWpGaD
Nabumetone—Dyspnoea—Capecitabine—kidney cancer	0.000109	0.000458	CcSEcCtD
Nabumetone—CYP1A2—Arachidonic acid metabolism—CYP1A1—kidney cancer	0.000109	0.00215	CbGpPWpGaD
Nabumetone—Dyspepsia—Capecitabine—kidney cancer	0.000108	0.000452	CcSEcCtD
Nabumetone—Visual impairment—Doxorubicin—kidney cancer	0.000107	0.000449	CcSEcCtD
Nabumetone—Asthenia—Paclitaxel—kidney cancer	0.000107	0.000449	CcSEcCtD
Nabumetone—Decreased appetite—Capecitabine—kidney cancer	0.000106	0.000447	CcSEcCtD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—kidney cancer	0.000106	0.00209	CbGpPWpGaD
Nabumetone—Nausea—Gemcitabine—kidney cancer	0.000106	0.000444	CcSEcCtD
Nabumetone—Fatigue—Capecitabine—kidney cancer	0.000105	0.000443	CcSEcCtD
Nabumetone—Pruritus—Paclitaxel—kidney cancer	0.000105	0.000443	CcSEcCtD
Nabumetone—Erythema multiforme—Doxorubicin—kidney cancer	0.000105	0.000441	CcSEcCtD
Nabumetone—Constipation—Capecitabine—kidney cancer	0.000105	0.000439	CcSEcCtD
Nabumetone—PTGS1—Biological oxidations—GSTP1—kidney cancer	0.000103	0.00204	CbGpPWpGaD
Nabumetone—Tinnitus—Doxorubicin—kidney cancer	0.000103	0.000435	CcSEcCtD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—kidney cancer	0.000103	0.00203	CbGpPWpGaD
Nabumetone—Diarrhoea—Paclitaxel—kidney cancer	0.000102	0.000428	CcSEcCtD
Nabumetone—Feeling abnormal—Capecitabine—kidney cancer	0.000101	0.000423	CcSEcCtD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—ANXA1—kidney cancer	0.0001	0.00198	CbGpPWpGaD
Nabumetone—Gastrointestinal pain—Capecitabine—kidney cancer	9.99e-05	0.00042	CcSEcCtD
Nabumetone—Chills—Doxorubicin—kidney cancer	9.95e-05	0.000418	CcSEcCtD
Nabumetone—PTGS2—C-MYB transcription factor network—KIT—kidney cancer	9.94e-05	0.00196	CbGpPWpGaD
Nabumetone—Arrhythmia—Doxorubicin—kidney cancer	9.91e-05	0.000416	CcSEcCtD
Nabumetone—Dizziness—Paclitaxel—kidney cancer	9.85e-05	0.000414	CcSEcCtD
Nabumetone—Alopecia—Doxorubicin—kidney cancer	9.8e-05	0.000412	CcSEcCtD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—GLIPR1—kidney cancer	9.8e-05	0.00193	CbGpPWpGaD
Nabumetone—Urticaria—Capecitabine—kidney cancer	9.71e-05	0.000408	CcSEcCtD
Nabumetone—Abdominal pain—Capecitabine—kidney cancer	9.66e-05	0.000406	CcSEcCtD
Nabumetone—Body temperature increased—Capecitabine—kidney cancer	9.66e-05	0.000406	CcSEcCtD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—kidney cancer	9.63e-05	0.0019	CbGpPWpGaD
Nabumetone—Flatulence—Doxorubicin—kidney cancer	9.51e-05	0.0004	CcSEcCtD
Nabumetone—PTGS1—Biological oxidations—GSTM1—kidney cancer	9.51e-05	0.00188	CbGpPWpGaD
Nabumetone—Tension—Doxorubicin—kidney cancer	9.47e-05	0.000398	CcSEcCtD
Nabumetone—Vomiting—Paclitaxel—kidney cancer	9.47e-05	0.000398	CcSEcCtD
Nabumetone—PTGS1—Selenium Micronutrient Network—RELA—kidney cancer	9.43e-05	0.00186	CbGpPWpGaD
Nabumetone—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	9.4e-05	0.00186	CbGpPWpGaD
Nabumetone—Rash—Paclitaxel—kidney cancer	9.39e-05	0.000395	CcSEcCtD
Nabumetone—Dermatitis—Paclitaxel—kidney cancer	9.38e-05	0.000394	CcSEcCtD
Nabumetone—Nervousness—Doxorubicin—kidney cancer	9.38e-05	0.000394	CcSEcCtD
Nabumetone—Headache—Paclitaxel—kidney cancer	9.33e-05	0.000392	CcSEcCtD
Nabumetone—CYP1A2—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	9.28e-05	0.00183	CbGpPWpGaD
Nabumetone—PTGS1—Selenium Micronutrient Network—PTGS2—kidney cancer	9.16e-05	0.00181	CbGpPWpGaD
Nabumetone—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—kidney cancer	9.05e-05	0.00179	CbGpPWpGaD
Nabumetone—PTGS1—Biological oxidations—CYP1A1—kidney cancer	9.01e-05	0.00178	CbGpPWpGaD
Nabumetone—Hypersensitivity—Capecitabine—kidney cancer	9e-05	0.000378	CcSEcCtD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—PAK1—kidney cancer	8.99e-05	0.00177	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—JUNB—kidney cancer	8.99e-05	0.00177	CbGpPWpGaD
Nabumetone—Ill-defined disorder—Doxorubicin—kidney cancer	8.96e-05	0.000376	CcSEcCtD
Nabumetone—Anaemia—Doxorubicin—kidney cancer	8.92e-05	0.000375	CcSEcCtD
Nabumetone—Agitation—Doxorubicin—kidney cancer	8.87e-05	0.000373	CcSEcCtD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—MYC—kidney cancer	8.86e-05	0.00175	CbGpPWpGaD
Nabumetone—Nausea—Paclitaxel—kidney cancer	8.85e-05	0.000372	CcSEcCtD
Nabumetone—Asthenia—Capecitabine—kidney cancer	8.77e-05	0.000369	CcSEcCtD
Nabumetone—Malaise—Doxorubicin—kidney cancer	8.7e-05	0.000366	CcSEcCtD
Nabumetone—Vertigo—Doxorubicin—kidney cancer	8.67e-05	0.000365	CcSEcCtD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—MAPK1—kidney cancer	8.67e-05	0.00171	CbGpPWpGaD
Nabumetone—Syncope—Doxorubicin—kidney cancer	8.66e-05	0.000364	CcSEcCtD
Nabumetone—Pruritus—Capecitabine—kidney cancer	8.65e-05	0.000363	CcSEcCtD
Nabumetone—Leukopenia—Doxorubicin—kidney cancer	8.64e-05	0.000363	CcSEcCtD
Nabumetone—Palpitations—Doxorubicin—kidney cancer	8.53e-05	0.000359	CcSEcCtD
Nabumetone—Loss of consciousness—Doxorubicin—kidney cancer	8.48e-05	0.000357	CcSEcCtD
Nabumetone—Cough—Doxorubicin—kidney cancer	8.42e-05	0.000354	CcSEcCtD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—EGR1—kidney cancer	8.41e-05	0.00166	CbGpPWpGaD
Nabumetone—Diarrhoea—Capecitabine—kidney cancer	8.36e-05	0.000351	CcSEcCtD
Nabumetone—Hypertension—Doxorubicin—kidney cancer	8.33e-05	0.00035	CcSEcCtD
Nabumetone—Anxiety—Doxorubicin—kidney cancer	8.19e-05	0.000344	CcSEcCtD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—KRAS—kidney cancer	8.19e-05	0.00162	CbGpPWpGaD
Nabumetone—Discomfort—Doxorubicin—kidney cancer	8.12e-05	0.000341	CcSEcCtD
Nabumetone—Dizziness—Capecitabine—kidney cancer	8.08e-05	0.00034	CcSEcCtD
Nabumetone—PTGS2—C-MYB transcription factor network—CDKN2A—kidney cancer	8.07e-05	0.00159	CbGpPWpGaD
Nabumetone—Dry mouth—Doxorubicin—kidney cancer	8.04e-05	0.000338	CcSEcCtD
Nabumetone—CYP1A2—Phase II conjugation—GSTP1—kidney cancer	7.95e-05	0.00157	CbGpPWpGaD
Nabumetone—Confusional state—Doxorubicin—kidney cancer	7.94e-05	0.000334	CcSEcCtD
Nabumetone—PTGS1—Metabolism—ACY1—kidney cancer	7.93e-05	0.00156	CbGpPWpGaD
Nabumetone—Anaphylactic shock—Doxorubicin—kidney cancer	7.88e-05	0.000331	CcSEcCtD
Nabumetone—Oedema—Doxorubicin—kidney cancer	7.88e-05	0.000331	CcSEcCtD
Nabumetone—Vomiting—Capecitabine—kidney cancer	7.77e-05	0.000327	CcSEcCtD
Nabumetone—Shock—Doxorubicin—kidney cancer	7.75e-05	0.000326	CcSEcCtD
Nabumetone—Thrombocytopenia—Doxorubicin—kidney cancer	7.71e-05	0.000324	CcSEcCtD
Nabumetone—Rash—Capecitabine—kidney cancer	7.71e-05	0.000324	CcSEcCtD
Nabumetone—Dermatitis—Capecitabine—kidney cancer	7.7e-05	0.000324	CcSEcCtD
Nabumetone—Headache—Capecitabine—kidney cancer	7.66e-05	0.000322	CcSEcCtD
Nabumetone—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	7.62e-05	0.0015	CbGpPWpGaD
Nabumetone—Hyperhidrosis—Doxorubicin—kidney cancer	7.62e-05	0.00032	CcSEcCtD
Nabumetone—PTGS2—C-MYB transcription factor network—CD4—kidney cancer	7.61e-05	0.0015	CbGpPWpGaD
Nabumetone—Anorexia—Doxorubicin—kidney cancer	7.51e-05	0.000316	CcSEcCtD
Nabumetone—PTGS2—Selenium Micronutrient Network—RELA—kidney cancer	7.49e-05	0.00148	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA2—kidney cancer	7.38e-05	0.00146	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN2B—kidney cancer	7.32e-05	0.00144	CbGpPWpGaD
Nabumetone—CYP1A2—Phase II conjugation—GSTM1—kidney cancer	7.3e-05	0.00144	CbGpPWpGaD
Nabumetone—Nausea—Capecitabine—kidney cancer	7.26e-05	0.000305	CcSEcCtD
Nabumetone—PTGS2—C-MYB transcription factor network—CDKN1B—kidney cancer	7.15e-05	0.00141	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—ABCB1—kidney cancer	7.15e-05	0.00141	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—kidney cancer	7.15e-05	0.00141	CbGpPWpGaD
Nabumetone—Insomnia—Doxorubicin—kidney cancer	7.13e-05	0.000299	CcSEcCtD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—RELA—kidney cancer	7.12e-05	0.0014	CbGpPWpGaD
Nabumetone—Paraesthesia—Doxorubicin—kidney cancer	7.07e-05	0.000297	CcSEcCtD
Nabumetone—Dyspnoea—Doxorubicin—kidney cancer	7.02e-05	0.000295	CcSEcCtD
Nabumetone—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	7.01e-05	0.00138	CbGpPWpGaD
Nabumetone—Somnolence—Doxorubicin—kidney cancer	7e-05	0.000294	CcSEcCtD
Nabumetone—Dyspepsia—Doxorubicin—kidney cancer	6.93e-05	0.000291	CcSEcCtD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—kidney cancer	6.92e-05	0.00137	CbGpPWpGaD
Nabumetone—Decreased appetite—Doxorubicin—kidney cancer	6.85e-05	0.000288	CcSEcCtD
Nabumetone—PTGS2—C-MYB transcription factor network—CCND1—kidney cancer	6.82e-05	0.00135	CbGpPWpGaD
Nabumetone—Fatigue—Doxorubicin—kidney cancer	6.79e-05	0.000285	CcSEcCtD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	6.76e-05	0.00133	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PDHB—kidney cancer	6.74e-05	0.00133	CbGpPWpGaD
Nabumetone—Constipation—Doxorubicin—kidney cancer	6.74e-05	0.000283	CcSEcCtD
Nabumetone—PTGS1—Biological oxidations—POMC—kidney cancer	6.72e-05	0.00133	CbGpPWpGaD
Nabumetone—CYP1A2—Biological oxidations—GSTT1—kidney cancer	6.71e-05	0.00132	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—kidney cancer	6.55e-05	0.00129	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—kidney cancer	6.55e-05	0.00129	CbGpPWpGaD
Nabumetone—Feeling abnormal—Doxorubicin—kidney cancer	6.49e-05	0.000273	CcSEcCtD
Nabumetone—CYP1A2—Arachidonic acid metabolism—PTGS2—kidney cancer	6.47e-05	0.00128	CbGpPWpGaD
Nabumetone—Gastrointestinal pain—Doxorubicin—kidney cancer	6.44e-05	0.000271	CcSEcCtD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—kidney cancer	6.41e-05	0.00127	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—CCBL1—kidney cancer	6.34e-05	0.00125	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—ACY1—kidney cancer	6.29e-05	0.00124	CbGpPWpGaD
Nabumetone—CYP1A2—Biological oxidations—PTGS1—kidney cancer	6.28e-05	0.00124	CbGpPWpGaD
Nabumetone—Urticaria—Doxorubicin—kidney cancer	6.26e-05	0.000263	CcSEcCtD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—kidney cancer	6.24e-05	0.00123	CbGpPWpGaD
Nabumetone—Body temperature increased—Doxorubicin—kidney cancer	6.23e-05	0.000262	CcSEcCtD
Nabumetone—Abdominal pain—Doxorubicin—kidney cancer	6.23e-05	0.000262	CcSEcCtD
Nabumetone—PTGS2—Disease—CCBL1—kidney cancer	6.01e-05	0.00119	CbGpPWpGaD
Nabumetone—Hypersensitivity—Doxorubicin—kidney cancer	5.8e-05	0.000244	CcSEcCtD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	5.73e-05	0.00113	CbGpPWpGaD
Nabumetone—CYP1A2—Phase 1 - Functionalization of compounds—POMC—kidney cancer	5.68e-05	0.00112	CbGpPWpGaD
Nabumetone—Asthenia—Doxorubicin—kidney cancer	5.65e-05	0.000238	CcSEcCtD
Nabumetone—Pruritus—Doxorubicin—kidney cancer	5.57e-05	0.000234	CcSEcCtD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—GLIPR1—kidney cancer	5.54e-05	0.00109	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—GLIPR1—kidney cancer	5.5e-05	0.00108	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PPAT—kidney cancer	5.5e-05	0.00108	CbGpPWpGaD
Nabumetone—PTGS2—C-MYB transcription factor network—MYC—kidney cancer	5.47e-05	0.00108	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—CDKN1B—kidney cancer	5.45e-05	0.00108	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—kidney cancer	5.45e-05	0.00108	CbGpPWpGaD
Nabumetone—PTGS2—Disease—AMER1—kidney cancer	5.43e-05	0.00107	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	5.43e-05	0.00107	CbGpPWpGaD
Nabumetone—Diarrhoea—Doxorubicin—kidney cancer	5.39e-05	0.000227	CcSEcCtD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	5.37e-05	0.00106	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PDHB—kidney cancer	5.35e-05	0.00106	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—IL2—kidney cancer	5.33e-05	0.00105	CbGpPWpGaD
Nabumetone—Dizziness—Doxorubicin—kidney cancer	5.21e-05	0.000219	CcSEcCtD
Nabumetone—PTGS2—Spinal Cord Injury—CCND1—kidney cancer	5.2e-05	0.00103	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—APC—kidney cancer	5.15e-05	0.00102	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—APRT—kidney cancer	5.11e-05	0.00101	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—FH—kidney cancer	5.11e-05	0.00101	CbGpPWpGaD
Nabumetone—PTGS2—C-MYB transcription factor network—KRAS—kidney cancer	5.06e-05	0.000998	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—CCBL1—kidney cancer	5.03e-05	0.000993	CbGpPWpGaD
Nabumetone—PTGS2—nephron—kidney cancer	5.01e-05	0.248	CbGeAlD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—MYC—kidney cancer	5.01e-05	0.000989	CbGpPWpGaD
Nabumetone—Vomiting—Doxorubicin—kidney cancer	5.01e-05	0.000211	CcSEcCtD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	4.99e-05	0.000986	CbGpPWpGaD
Nabumetone—Rash—Doxorubicin—kidney cancer	4.97e-05	0.000209	CcSEcCtD
Nabumetone—Dermatitis—Doxorubicin—kidney cancer	4.96e-05	0.000209	CcSEcCtD
Nabumetone—Headache—Doxorubicin—kidney cancer	4.94e-05	0.000207	CcSEcCtD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—kidney cancer	4.9e-05	0.000968	CbGpPWpGaD
Nabumetone—CYP1A2—urine—kidney cancer	4.86e-05	0.24	CbGeAlD
Nabumetone—PTGS1—Metabolism—GPC3—kidney cancer	4.8e-05	0.000948	CbGpPWpGaD
Nabumetone—Nausea—Doxorubicin—kidney cancer	4.68e-05	0.000197	CcSEcCtD
Nabumetone—PTGS1—Metabolism—CA2—kidney cancer	4.67e-05	0.000922	CbGpPWpGaD
Nabumetone—CYP1A2—Biological oxidations—GSTP1—kidney cancer	4.65e-05	0.000917	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—kidney cancer	4.63e-05	0.000914	CbGpPWpGaD
Nabumetone—CYP1A2—Metapathway biotransformation—GSTP1—kidney cancer	4.58e-05	0.000905	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—ALAD—kidney cancer	4.55e-05	0.000899	CbGpPWpGaD
Nabumetone—PTGS2—Disease—GPC3—kidney cancer	4.55e-05	0.000899	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	4.55e-05	0.000898	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—ST3GAL2—kidney cancer	4.44e-05	0.000877	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—GLIPR1—kidney cancer	4.36e-05	0.000861	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PPAT—kidney cancer	4.36e-05	0.000861	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—ALDH1A1—kidney cancer	4.34e-05	0.000857	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	4.31e-05	0.00085	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—MAPK3—kidney cancer	4.29e-05	0.000846	CbGpPWpGaD
Nabumetone—CYP1A2—Biological oxidations—GSTM1—kidney cancer	4.27e-05	0.000843	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	4.26e-05	0.000842	CbGpPWpGaD
Nabumetone—PTGS2—Disease—ST3GAL2—kidney cancer	4.21e-05	0.000831	CbGpPWpGaD
Nabumetone—CYP1A2—Metapathway biotransformation—GSTM1—kidney cancer	4.21e-05	0.000831	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—MYC—kidney cancer	4.17e-05	0.000823	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—SLC5A3—kidney cancer	4.17e-05	0.000822	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PGK1—kidney cancer	4.17e-05	0.000822	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—LDHB—kidney cancer	4.08e-05	0.000806	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—MAPK1—kidney cancer	4.08e-05	0.000805	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—APRT—kidney cancer	4.06e-05	0.0008	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—FH—kidney cancer	4.06e-05	0.0008	CbGpPWpGaD
Nabumetone—CYP1A2—Biological oxidations—CYP1A1—kidney cancer	4.05e-05	0.000799	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—RAF1—kidney cancer	4.05e-05	0.000798	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—kidney cancer	4e-05	0.00079	CbGpPWpGaD
Nabumetone—CYP1A2—Metapathway biotransformation—CYP1A1—kidney cancer	3.99e-05	0.000788	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	3.96e-05	0.000782	CbGpPWpGaD
Nabumetone—PTGS2—Disease—PGK1—kidney cancer	3.95e-05	0.000779	CbGpPWpGaD
Nabumetone—PTGS2—Disease—SLC5A3—kidney cancer	3.95e-05	0.000779	CbGpPWpGaD
Nabumetone—PTGS2—Disease—LDHB—kidney cancer	3.87e-05	0.000764	CbGpPWpGaD
Nabumetone—PTGS2—Disease—SFRP2—kidney cancer	3.87e-05	0.000764	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—GPC3—kidney cancer	3.81e-05	0.000753	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—CA2—kidney cancer	3.71e-05	0.000732	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—kidney cancer	3.71e-05	0.000731	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—ALAD—kidney cancer	3.62e-05	0.000713	CbGpPWpGaD
Nabumetone—PTGS2—Disease—TCEB2—kidney cancer	3.61e-05	0.000713	CbGpPWpGaD
Nabumetone—PTGS2—Disease—TCEB1—kidney cancer	3.61e-05	0.000713	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—ACY1—kidney cancer	3.56e-05	0.000703	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—CA9—kidney cancer	3.54e-05	0.000699	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—kidney cancer	3.54e-05	0.000698	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—ST3GAL2—kidney cancer	3.53e-05	0.000696	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—kidney cancer	3.53e-05	0.000696	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—kidney cancer	3.5e-05	0.000691	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	3.46e-05	0.000683	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—ALDH1A1—kidney cancer	3.45e-05	0.000681	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—TP53—kidney cancer	3.42e-05	0.000676	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—kidney cancer	3.41e-05	0.000674	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PGK1—kidney cancer	3.31e-05	0.000653	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—SLC5A3—kidney cancer	3.31e-05	0.000653	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—LDHB—kidney cancer	3.24e-05	0.00064	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—kidney cancer	3.08e-05	0.000608	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	3.04e-05	0.000599	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PDHB—kidney cancer	3.03e-05	0.000598	CbGpPWpGaD
Nabumetone—CYP1A2—Biological oxidations—POMC—kidney cancer	3.02e-05	0.000596	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—CRABP1—kidney cancer	3.01e-05	0.000594	CbGpPWpGaD
Nabumetone—PTGS2—Disease—RPL14—kidney cancer	2.93e-05	0.000579	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK3—kidney cancer	2.92e-05	0.000575	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—CCBL1—kidney cancer	2.85e-05	0.000562	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—kidney cancer	2.84e-05	0.00056	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—CA9—kidney cancer	2.81e-05	0.000555	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—ITPR2—kidney cancer	2.8e-05	0.000552	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK1—kidney cancer	2.77e-05	0.000548	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	2.75e-05	0.000542	CbGpPWpGaD
Nabumetone—PTGS2—Disease—ITPR2—kidney cancer	2.65e-05	0.000524	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—kidney cancer	2.62e-05	0.000517	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—POMC—kidney cancer	2.58e-05	0.000509	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	2.58e-05	0.000508	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—ACHE—kidney cancer	2.55e-05	0.000504	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—GSTT1—kidney cancer	2.55e-05	0.000504	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—GLIPR1—kidney cancer	2.47e-05	0.000487	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PPAT—kidney cancer	2.47e-05	0.000487	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	2.44e-05	0.000481	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—SCARB1—kidney cancer	2.42e-05	0.000477	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	2.41e-05	0.000476	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—kidney cancer	2.41e-05	0.000475	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—CRABP1—kidney cancer	2.39e-05	0.000472	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PSMD7—kidney cancer	2.35e-05	0.000463	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	2.33e-05	0.00046	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—FH—kidney cancer	2.3e-05	0.000453	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—APRT—kidney cancer	2.3e-05	0.000453	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	2.24e-05	0.000443	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—BCHE—kidney cancer	2.22e-05	0.000439	CbGpPWpGaD
Nabumetone—PTGS2—Disease—PSMD7—kidney cancer	2.22e-05	0.000439	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—ITPR2—kidney cancer	2.22e-05	0.000439	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—SLC5A5—kidney cancer	2.2e-05	0.000434	CbGpPWpGaD
Nabumetone—MPO—renal system—kidney cancer	2.17e-05	0.107	CbGeAlD
Nabumetone—CYP1A2—Metabolism—GPC3—kidney cancer	2.16e-05	0.000426	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—SLC2A1—kidney cancer	2.12e-05	0.000419	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—CA2—kidney cancer	2.1e-05	0.000414	CbGpPWpGaD
Nabumetone—MPO—kidney—kidney cancer	2.1e-05	0.104	CbGeAlD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	2.06e-05	0.000406	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—POMC—kidney cancer	2.05e-05	0.000404	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—ALAD—kidney cancer	2.05e-05	0.000404	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—ACHE—kidney cancer	2.03e-05	0.0004	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—GSTT1—kidney cancer	2.03e-05	0.0004	CbGpPWpGaD
Nabumetone—PTGS2—Disease—SLC2A1—kidney cancer	2.01e-05	0.000397	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—ST3GAL2—kidney cancer	2e-05	0.000394	CbGpPWpGaD
Nabumetone—PTGS2—Disease—JUNB—kidney cancer	2e-05	0.000394	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—ALDH1A1—kidney cancer	1.95e-05	0.000385	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—SCARB1—kidney cancer	1.92e-05	0.000379	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PTGS1—kidney cancer	1.9e-05	0.000375	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PGK1—kidney cancer	1.87e-05	0.000369	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—SLC5A3—kidney cancer	1.87e-05	0.000369	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PSMD7—kidney cancer	1.86e-05	0.000368	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—LDHB—kidney cancer	1.83e-05	0.000362	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1.8e-05	0.000354	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—GSTP1—kidney cancer	1.77e-05	0.000349	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—BCHE—kidney cancer	1.77e-05	0.000348	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—SLC5A5—kidney cancer	1.74e-05	0.000344	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—SLC2A1—kidney cancer	1.68e-05	0.000332	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—ABCB1—kidney cancer	1.68e-05	0.000331	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—GSTM1—kidney cancer	1.63e-05	0.000321	CbGpPWpGaD
Nabumetone—PTGS2—Disease—CDKN2B—kidney cancer	1.63e-05	0.000321	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—CA9—kidney cancer	1.59e-05	0.000314	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	1.55e-05	0.000307	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—CYP1A1—kidney cancer	1.54e-05	0.000304	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1.43e-05	0.000281	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—GSTP1—kidney cancer	1.4e-05	0.000277	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—CRABP1—kidney cancer	1.35e-05	0.000267	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—ABCB1—kidney cancer	1.33e-05	0.000262	CbGpPWpGaD
Nabumetone—PTGS2—Disease—HIF1A—kidney cancer	1.3e-05	0.000256	CbGpPWpGaD
Nabumetone—PTGS2—Disease—TSC2—kidney cancer	1.3e-05	0.000256	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—GSTM1—kidney cancer	1.29e-05	0.000255	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.27e-05	0.00025	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—ITPR2—kidney cancer	1.26e-05	0.000248	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—CYP1A1—kidney cancer	1.22e-05	0.000242	CbGpPWpGaD
Nabumetone—CYP1A2—renal system—kidney cancer	1.19e-05	0.0588	CbGeAlD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.16e-05	0.000229	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—POMC—kidney cancer	1.15e-05	0.000227	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—ACHE—kidney cancer	1.15e-05	0.000226	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—GSTT1—kidney cancer	1.15e-05	0.000226	CbGpPWpGaD
Nabumetone—PTGS2—Disease—APC—kidney cancer	1.14e-05	0.000226	CbGpPWpGaD
Nabumetone—PTGS2—Disease—KIT—kidney cancer	1.14e-05	0.000226	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—SCARB1—kidney cancer	1.09e-05	0.000214	CbGpPWpGaD
Nabumetone—PTGS2—Disease—BRAF—kidney cancer	1.08e-05	0.000212	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PTGS1—kidney cancer	1.07e-05	0.000212	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PSMD7—kidney cancer	1.05e-05	0.000208	CbGpPWpGaD
Nabumetone—PTGS1—renal system—kidney cancer	1.03e-05	0.051	CbGeAlD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.01e-05	0.000198	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—BCHE—kidney cancer	9.99e-06	0.000197	CbGpPWpGaD
Nabumetone—PTGS1—kidney—kidney cancer	9.95e-06	0.0493	CbGeAlD
Nabumetone—CYP1A2—Metabolism—SLC5A5—kidney cancer	9.87e-06	0.000195	CbGpPWpGaD
Nabumetone—PTGS2—renal system—kidney cancer	9.84e-06	0.0487	CbGeAlD
Nabumetone—CYP1A2—Metabolism—SLC2A1—kidney cancer	9.53e-06	0.000188	CbGpPWpGaD
Nabumetone—PTGS2—kidney—kidney cancer	9.51e-06	0.0471	CbGeAlD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	9.25e-06	0.000182	CbGpPWpGaD
Nabumetone—PTGS1—cardiac atrium—kidney cancer	9.22e-06	0.0456	CbGeAlD
Nabumetone—PTGS1—Metabolism—PTGS2—kidney cancer	9.17e-06	0.000181	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—POMC—kidney cancer	9.12e-06	0.00018	CbGpPWpGaD
Nabumetone—PTGS2—Disease—RAF1—kidney cancer	8.98e-06	0.000177	CbGpPWpGaD
Nabumetone—PTGS2—Disease—ERBB2—kidney cancer	8.89e-06	0.000175	CbGpPWpGaD
Nabumetone—PTGS2—Disease—MTOR—kidney cancer	8.77e-06	0.000173	CbGpPWpGaD
Nabumetone—PTGS2—Disease—CD4—kidney cancer	8.75e-06	0.000173	CbGpPWpGaD
Nabumetone—PTGS2—Disease—CDKN1B—kidney cancer	8.23e-06	0.000162	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	8.06e-06	0.000159	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PTEN—kidney cancer	7.99e-06	0.000158	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—GSTP1—kidney cancer	7.95e-06	0.000157	CbGpPWpGaD
Nabumetone—PTGS2—Disease—CTNNB1—kidney cancer	7.78e-06	0.000153	CbGpPWpGaD
Nabumetone—PTGS2—Disease—PTEN—kidney cancer	7.58e-06	0.00015	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—ABCB1—kidney cancer	7.52e-06	0.000149	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—GSTM1—kidney cancer	7.31e-06	0.000144	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—CYP1A1—kidney cancer	6.93e-06	0.000137	CbGpPWpGaD
Nabumetone—PTGS2—Disease—MAPK3—kidney cancer	6.48e-06	0.000128	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PTEN—kidney cancer	6.35e-06	0.000125	CbGpPWpGaD
Nabumetone—PTGS2—Disease—MYC—kidney cancer	6.3e-06	0.000124	CbGpPWpGaD
Nabumetone—PTGS2—Disease—MAPK1—kidney cancer	6.16e-06	0.000122	CbGpPWpGaD
Nabumetone—PTGS2—Disease—KRAS—kidney cancer	5.82e-06	0.000115	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	5.69e-06	0.000112	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PIK3CA—kidney cancer	5.64e-06	0.000111	CbGpPWpGaD
Nabumetone—PTGS2—Disease—PIK3CA—kidney cancer	5.35e-06	0.000106	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—POMC—kidney cancer	5.16e-06	0.000102	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PIK3CA—kidney cancer	4.48e-06	8.84e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PTGS2—kidney cancer	4.12e-06	8.13e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PTEN—kidney cancer	3.59e-06	7.09e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PIK3CA—kidney cancer	2.53e-06	5e-05	CbGpPWpGaD
